Andrew Hopkins, Exscientia CEO

Bris­tol My­ers ex­pands Cel­gene-era deal with Ex­sci­en­tia, tak­ing its AI R&D en­gine to the next step

One day af­ter tak­ing a shot on an an­ti-TIG­IT bis­pe­cif­ic from Agenus, Bris­tol My­ers Squibb is still in a deal­mak­ing mood.

For Wednes­day’s chas­er …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA